Dr. Helen I. Torley is the CEO of Halozyme Therapeutics, Inc., bringing over 30 years of experience in the biotechnology and pharmaceutical industry. She earned her M.B.Ch.B. from the University of Glasgow. Before becoming CEO in 2014, she held significant...
Dr. Helen I. Torley is the CEO of Halozyme Therapeutics, Inc., bringing over 30 years of experience in the biotechnology and pharmaceutical industry. She earned her M.B.Ch.B. from the University of Glasgow. Before becoming CEO in 2014, she held significant roles at Onyx Pharmaceuticals and Amgen, where she successfully launched several drugs including Kyprolis and Prolia. Under her leadership, Halozyme has seen a strategic shift that contributed to its successes in drug development and commercialization. Dr. Torley also has a strong background in medicine, having trained as a doctor and worked in clinical settings. Her ability to connect scientific advances with business strategies has been key to Halozyme’s growth. Notably, Dr. Torley’s total compensation for 2022 was around $1.4 million, which reflects her performance-based bonus structure and stock vesting achievements. Her trading activities with Halozyme stocks indicate a significant confidence in her work, with insider trading values reaching as high as $54.53 million in early 2021. This suggests not just a commitment to the company but also a vested interest in its future.